Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 354

1.

Application of System Dynamics to Inform a Model of Adolescent SBIRT Implementation in Primary Care Settings.

Lounsbury DW, Mitchell SG, Dusek KA, Li JZ, Kirk AS, Oros M, Hosler C, Schwartz RP, Gryczynski J, Monico LB, Brown BS.

J Behav Health Serv Res. 2019 Jun 18. doi: 10.1007/s11414-019-09650-y. [Epub ahead of print]

PMID:
31214935
2.

A Double-Blind Placebo Controlled Study of Intranasal Oxytocin's Effect on Emotion Recognition and Visual Attention in Outpatients with Emotional Disorders.

Rutter LA, Norton DJ, Brown BS, Brown TA.

Cognit Ther Res. 2019 Jun;43(3):523-534. doi: 10.1007/s10608-018-9974-x. Epub 2018 Nov 3.

PMID:
31130760
3.

A Comparison of Screening Practices for Adolescents in Primary Care After Implementation of Screening, Brief Intervention, and Referral to Treatment.

Monico LB, Mitchell SG, Dusek K, Gryczynski J, Schwartz RP, Oros M, Hosler C, O'Grady KE, Brown BS.

J Adolesc Health. 2019 Jul;65(1):46-50. doi: 10.1016/j.jadohealth.2018.12.005. Epub 2019 Mar 6.

PMID:
30850312
4.

Discovery of ABBV-4083, a novel analog of Tylosin A that has potent anti-Wolbachia and anti-filarial activity.

von Geldern TW, Morton HE, Clark RF, Brown BS, Johnston KL, Ford L, Specht S, Carr RA, Stolarik DF, Ma J, Rieser MJ, Struever D, Frohberger SJ, Koschel M, Ehrens A, Turner JD, Hübner MP, Hoerauf A, Taylor MJ, Ward SA, Marsh K, Kempf DJ.

PLoS Negl Trop Dis. 2019 Feb 28;13(2):e0007159. doi: 10.1371/journal.pntd.0007159. eCollection 2019 Feb.

5.

Disclosure of Adolescent Substance Use in Primary Care: Comparison of Routine Clinical Screening and Anonymous Research Interviews.

Gryczynski J, Mitchell SG, Schwartz RP, Kelly SM, Dušek K, Monico L, O'Grady KE, Brown BS, Oros M, Hosler C.

J Adolesc Health. 2019 Apr;64(4):541-543. doi: 10.1016/j.jadohealth.2018.10.009. Epub 2018 Dec 18.

PMID:
30578116
6.

Ultrafast measurements of the dynamics of single nanostructures: a review.

Beane G, Devkota T, Brown BS, Hartland GV.

Rep Prog Phys. 2019 Jan;82(1):016401. doi: 10.1088/1361-6633/aaea4b. Epub 2018 Nov 28.

PMID:
30485256
7.

Synthesis of ABBV-168, a 2'-Bromouridine for the Treatment of Hepatitis C.

Voight EA, Brown BS, Greszler SN, Halvorsen GT, Zhao G, Kruger AW, Hartung J, Lukin KA, Martinez SR, Moschetta EG, Tudesco MT, Ide ND.

J Org Chem. 2019 Apr 19;84(8):4723-4734. doi: 10.1021/acs.joc.8b02341. Epub 2018 Nov 19.

PMID:
30412402
8.

Identification of Selective Dual ROCK1 and ROCK2 Inhibitors Using Structure-Based Drug Design.

Hobson AD, Judge RA, Aguirre AL, Brown BS, Cui Y, Ding P, Dominguez E, DiGiammarino E, Egan DA, Freiberg GM, Gopalakrishnan SM, Harris CM, Honore MP, Kage KL, Kapecki NJ, Ling C, Ma J, Mack H, Mamo M, Maurus S, McRae B, Moore NS, Mueller BK, Mueller R, Namovic MT, Patel K, Pratt SD, Putman CB, Queeney KL, Sarris KK, Schaffter LM, Stoll V, Vasudevan A, Wang L, Wang L, Wirthl W, Yach K.

J Med Chem. 2018 Dec 27;61(24):11074-11100. doi: 10.1021/acs.jmedchem.8b01098. Epub 2018 Dec 12.

PMID:
30384606
9.

Identification of Quinoline-Based RIP2 Kinase Inhibitors with an Improved Therapeutic Index to the hERG Ion Channel.

Haile PA, Casillas LN, Bury MJ, Mehlmann JF, Singhaus R Jr, Charnley AK, Hughes TV, DeMartino MP, Wang GZ, Romano JJ, Dong X, Plotnikov NV, Lakdawala AS, Convery MA, Votta BJ, Lipshutz DB, Desai BM, Swift B, Capriotti CA, Berger SB, Mahajan MK, Reilly MA, Rivera EJ, Sun HH, Nagilla R, LePage C, Ouellette MT, Totoritis RD, Donovan BT, Brown BS, Chaudhary KW, Gough PJ, Bertin J, Marquis RW.

ACS Med Chem Lett. 2018 Sep 26;9(10):1039-1044. doi: 10.1021/acsmedchemlett.8b00344. eCollection 2018 Oct 11.

PMID:
30344914
10.

Imaging features and safety and efficacy of endovascular stroke treatment: a meta-analysis of individual patient-level data.

Román LS, Menon BK, Blasco J, Hernández-Pérez M, Dávalos A, Majoie CBLM, Campbell BCV, Guillemin F, Lingsma H, Anxionnat R, Epstein J, Saver JL, Marquering H, Wong JH, Lopes D, Reimann G, Desal H, Dippel DWJ, Coutts S, du Mesnil de Rochemont R, Yavagal D, Ferre JC, Roos YBWEM, Liebeskind DS, Lenthall R, Molina C, Al Ajlan FS, Reddy V, Dowlatshahi D, Sourour NA, Oppenheim C, Mitha AP, Davis SM, Weimar C, van Oostenbrugge RJ, Cobo E, Kleinig TJ, Donnan GA, van der Lugt A, Demchuk AM, Berkhemer OA, Boers AMM, Ford GA, Muir KW, Brown BS, Jovin T, van Zwam WH, Mitchell PJ, Hill MD, White P, Bracard S, Goyal M; HERMES collaborators.

Lancet Neurol. 2018 Oct;17(10):895-904. doi: 10.1016/S1474-4422(18)30242-4. Epub 2018 Sep 18. Erratum in: Lancet Neurol. 2018 Dec;17(12):e2-e3.

PMID:
30264728
11.

Start-Up Costs of SBIRT Implementation for Adolescents in Urban U.S. Federally Qualified Health Centers.

Barbosa C, Wedehase B, Dunlap L, Mitchell SG, Dusek K, Schwartz RP, Gryzcynski J, Kirk AS, Oros M, Hosler C, O'Grady KE, Brown BS.

J Stud Alcohol Drugs. 2018 May;79(3):447-454.

12.

Strong Exciton-Plasmon Coupling in Silver Nanowire Nanocavities.

Beane G, Brown BS, Johns P, Devkota T, Hartland GV.

J Phys Chem Lett. 2018 Apr 5;9(7):1676-1681. doi: 10.1021/acs.jpclett.8b00313. Epub 2018 Mar 20.

PMID:
29547298
13.

Metabolic Network Analysis and Metatranscriptomics Reveal Auxotrophies and Nutrient Sources of the Cosmopolitan Freshwater Microbial Lineage acI.

Hamilton JJ, Garcia SL, Brown BS, Oyserman BO, Moya-Flores F, Bertilsson S, Malmstrom RR, Forest KT, McMahon KD.

mSystems. 2017 Aug 29;2(4). pii: e00091-17. doi: 10.1128/mSystems.00091-17. eCollection 2017 Jul-Aug.

14.

The Clinical Manifestations and Genetic Implications of Baraitser-Winter Syndrome Type 2.

Allawh TC, Brown BS.

J Pediatr Genet. 2017 Jun;6(2):107-110. doi: 10.1055/s-0036-1593967. Epub 2016 Nov 10.

15.

Ghee Butter as a Therapeutic Delivery System.

Balasubramanian K, Evangelopoulos M, Brown BS, Parodi A, Celia C, Yazdi IK, Tasciotti E.

J Nanosci Nanotechnol. 2017 Feb;17(2):977-82.

PMID:
29671486
16.

Cardiotoxicity screening with simultaneous optogenetic pacing, voltage imaging and calcium imaging.

Dempsey GT, Chaudhary KW, Atwater N, Nguyen C, Brown BS, McNeish JD, Cohen AE, Kralj JM.

J Pharmacol Toxicol Methods. 2016 Sep-Oct;81:240-50. doi: 10.1016/j.vascn.2016.05.003. Epub 2016 May 13.

PMID:
27184445
17.

Novel tricyclics (e.g., GSK945237) as potent inhibitors of bacterial type IIA topoisomerases.

Miles TJ, Hennessy AJ, Bax B, Brooks G, Brown BS, Brown P, Cailleau N, Chen D, Dabbs S, Davies DT, Esken JM, Giordano I, Hoover JL, Jones GE, Kusalakumari Sukmar SK, Markwell RE, Minthorn EA, Rittenhouse S, Gwynn MN, Pearson ND.

Bioorg Med Chem Lett. 2016 May 15;26(10):2464-2469. doi: 10.1016/j.bmcl.2016.03.106. Epub 2016 Mar 31.

PMID:
27055939
18.

Matching Treatment to Rhetoric - A Challenge to Policy and Programming.

Flynn PM, Brown BS.

J Subst Abuse Treat. 2016 May;64:1-2. doi: 10.1016/j.jsat.2015.06.025. Epub 2015 Dec 8. No abstract available.

19.

Cell source determines the immunological impact of biomimetic nanoparticles.

Evangelopoulos M, Parodi A, Martinez JO, Yazdi IK, Cevenini A, van de Ven AL, Quattrocchi N, Boada C, Taghipour N, Corbo C, Brown BS, Scaria S, Liu X, Ferrari M, Tasciotti E.

Biomaterials. 2016 Mar;82:168-77. doi: 10.1016/j.biomaterials.2015.11.054. Epub 2015 Dec 2.

20.

SBIRT Implementation for Adolescents in Urban Federally Qualified Health Centers.

Mitchell SG, Schwartz RP, Kirk AS, Dusek K, Oros M, Hosler C, Gryczynski J, Barbosa C, Dunlap L, Lounsbury D, O'Grady KE, Brown BS.

J Subst Abuse Treat. 2016 Jan;60:81-90. doi: 10.1016/j.jsat.2015.06.011. Epub 2015 Jun 26.

21.

In Support of a National Treatment Evaluation Study.

Brown BS, Flynn PM.

Subst Use Misuse. 2015;50(8-9):1051-4. doi: 10.3109/10826084.2015.1007660.

PMID:
25775031
22.

Misrepresenting the Accomplishments of Treatment.

Flynn PM, Brown BS.

Subst Use Misuse. 2015;50(8-9):978-80. doi: 10.3109/10826084.2015.1007673.

PMID:
25774461
23.

Bromelain surface modification increases the diffusion of silica nanoparticles in the tumor extracellular matrix.

Parodi A, Haddix SG, Taghipour N, Scaria S, Taraballi F, Cevenini A, Yazdi IK, Corbo C, Palomba R, Khaled SZ, Martinez JO, Brown BS, Isenhart L, Tasciotti E.

ACS Nano. 2014 Oct 28;8(10):9874-83. doi: 10.1021/nn502807n. Epub 2014 Sep 17.

24.

Compound heterozygous CORO1A mutations in siblings with a mucocutaneous-immunodeficiency syndrome of epidermodysplasia verruciformis-HPV, molluscum contagiosum and granulomatous tuberculoid leprosy.

Stray-Pedersen A, Jouanguy E, Crequer A, Bertuch AA, Brown BS, Jhangiani SN, Muzny DM, Gambin T, Sorte H, Sasa G, Metry D, Campbell J, Sockrider MM, Dishop MK, Scollard DM, Gibbs RA, Mace EM, Orange JS, Lupski JR, Casanova JL, Noroski LM.

J Clin Immunol. 2014 Oct;34(7):871-90. doi: 10.1007/s10875-014-0074-8. Epub 2014 Jul 30.

25.

Etoposide-loaded immunoliposomes as active targeting agents for GD2-positive malignancies.

Brown BS, Patanam T, Mobli K, Celia C, Zage PE, Bean AJ, Tasciotti E.

Cancer Biol Ther. 2014 Jul;15(7):851-61. doi: 10.4161/cbt.28875. Epub 2014 Apr 22.

26.

Novel hydroxyl tricyclics (e.g., GSK966587) as potent inhibitors of bacterial type IIA topoisomerases.

Miles TJ, Hennessy AJ, Bax B, Brooks G, Brown BS, Brown P, Cailleau N, Chen D, Dabbs S, Davies DT, Esken JM, Giordano I, Hoover JL, Huang J, Jones GE, Sukmar SK, Spitzfaden C, Markwell RE, Minthorn EA, Rittenhouse S, Gwynn MN, Pearson ND.

Bioorg Med Chem Lett. 2013 Oct 1;23(19):5437-41. doi: 10.1016/j.bmcl.2013.07.013. Epub 2013 Jul 17.

PMID:
23968823
27.

Predicting drug-induced QT prolongation and torsades de pointes: a review of preclinical endpoint measures.

Townsend C, Brown BS.

Curr Protoc Pharmacol. 2013 Jun;Chapter 10:Unit 10.16. doi: 10.1002/0471141755.ph1016s61. Review.

PMID:
23744708
28.

Short and long term, in vitro and in vivo correlations of cellular and tissue responses to mesoporous silicon nanovectors.

Martinez JO, Boada C, Yazdi IK, Evangelopoulos M, Brown BS, Liu X, Ferrari M, Tasciotti E.

Small. 2013 May 27;9(9-10):1722-33. doi: 10.1002/smll.201201939. Epub 2012 Dec 16.

29.

Synthetic nanoparticles functionalized with biomimetic leukocyte membranes possess cell-like functions.

Parodi A, Quattrocchi N, van de Ven AL, Chiappini C, Evangelopoulos M, Martinez JO, Brown BS, Khaled SZ, Yazdi IK, Enzo MV, Isenhart L, Ferrari M, Tasciotti E.

Nat Nanotechnol. 2013 Jan;8(1):61-8. doi: 10.1038/nnano.2012.212. Epub 2012 Dec 16.

30.

Multifunctional to multistage delivery systems: The evolution of nanoparticles for biomedical applications.

Martinez JO, Brown BS, Quattrocchi N, Evangelopoulos M, Ferrari M, Tasciotti E.

Chin Sci Bull. 2012 Nov 1;57(31):3961-3971.

31.

UBE4B levels are correlated with clinical outcomes in neuroblastoma patients and with altered neuroblastoma cell proliferation and sensitivity to epidermal growth factor receptor inhibitors.

Zage PE, Sirisaengtaksin N, Liu Y, Gireud M, Brown BS, Palla S, Richards KN, Hughes DP, Bean AJ.

Cancer. 2013 Feb 15;119(4):915-23. doi: 10.1002/cncr.27785. Epub 2012 Sep 18.

32.

Helicopter EMS Transport Outcomes Literature: Annotated Review of Articles Published 2007-2011.

Brown BS, Pogue KA, Williams E, Hatfield J, Thomas M, Arthur A, Thomas SH.

Emerg Med Int. 2012;2012:876703. doi: 10.1155/2012/876703. Epub 2012 Jan 11.

33.

HIV sex-risk behaviors among in- versus out-of-treatment heroin-addicted adults.

Mitchell SG, Kelly SM, Brown BS, O'Grady KE, Schwartz RP.

Am J Drug Alcohol Abuse. 2012 Jul;38(4):328-33. doi: 10.3109/00952990.2011.643993. Epub 2012 Jan 13.

34.

A comparison of attitudes toward opioid agonist treatment among short-term buprenorphine patients.

Kelly SM, Brown BS, Katz EC, O'Grady KE, Mitchell SG, King S, Schwartz RP.

Am J Drug Alcohol Abuse. 2012 May;38(3):233-8. doi: 10.3109/00952990.2011.643983. Epub 2012 Jan 13.

35.

TRPV1 antagonist, A-889425, inhibits mechanotransmission in a subclass of rat primary afferent neurons following peripheral inflammation.

Brederson JD, Chu KL, Reilly RM, Brown BS, Kym PR, Jarvis MF, McGaraughty S.

Synapse. 2012 Mar;66(3):187-95. doi: 10.1002/syn.20992. Epub 2011 Dec 13.

PMID:
21953601
36.

Redefining retention: recovery from the patient's perspective.

Mitchell SG, Morioka R, Reisinger HS, Peterson JA, Kelly SM, Agar MH, Brown BS, O'Grady KE, Schwartz RP.

J Psychoactive Drugs. 2011 Apr-Jun;43(2):99-107.

37.

Predictors of methadone treatment retention from a multi-site study: a survival analysis.

Kelly SM, O'Grady KE, Mitchell SG, Brown BS, Schwartz RP.

Drug Alcohol Depend. 2011 Sep 1;117(2-3):170-5. doi: 10.1016/j.drugalcdep.2011.01.008. Epub 2011 Feb 9.

38.

Transitioning opioid-dependent patients from detoxification to long-term treatment: efficacy of intensive role induction.

Katz EC, Brown BS, Schwartz RP, O'Grady KE, King SD, Gandhi D.

Drug Alcohol Depend. 2011 Aug 1;117(1):24-30. doi: 10.1016/j.drugalcdep.2010.12.024. Epub 2011 Feb 1.

39.

Implementation research: Issues and prospects.

Flynn PM, Brown BS.

Addict Behav. 2011 Jun;36(6):566-9. doi: 10.1016/j.addbeh.2010.12.020. Epub 2010 Dec 21.

40.

Antecedents and correlates of methadone treatment entry: a comparison of out-of-treatment and in-treatment cohorts.

Schwartz RP, Kelly SM, O'Grady KE, Mitchell SG, Brown BS.

Drug Alcohol Depend. 2011 May 1;115(1-2):23-9. doi: 10.1016/j.drugalcdep.2010.10.016. Epub 2010 Dec 3.

41.

Assessment of physical fitness aspects and their relationship to firefighters' job abilities.

Michaelides MA, Parpa KM, Henry LJ, Thompson GB, Brown BS.

J Strength Cond Res. 2011 Apr;25(4):956-65. doi: 10.1519/JSC.0b013e3181cc23ea.

PMID:
20703167
42.

The effect of starting point placement technique on thoracic transverse process strength: an ex vivo biomechanical study.

Brown BS, McIff TE, Glattes RC, Burton DC, Asher MA.

Scoliosis. 2010 Jul 13;5:14. doi: 10.1186/1748-7161-5-14.

43.

The role of patient satisfaction in methadone treatment.

Kelly SM, O'Grady KE, Brown BS, Mitchell SG, Schwartz RP.

Am J Drug Alcohol Abuse. 2010 May;36(3):150-4. doi: 10.3109/00952991003736371.

44.

Discovery of TRPV1 antagonist ABT-116.

Brown BS, Keddy R, Perner RJ, DiDomenico S, Koenig JR, Jinkerson TK, Hannick SM, McDonald HA, Bianchi BR, Honore P, Puttfarcken PS, Moreland RB, Marsh KC, Faltynek CR, Lee CH.

Bioorg Med Chem Lett. 2010 Jun 1;20(11):3291-4. doi: 10.1016/j.bmcl.2010.04.047. Epub 2010 Apr 14.

PMID:
20457518
45.

The relationship of social support to treatment entry and engagement: the Community Assessment Inventory.

Kelly SM, O'Grady KE, Schwartz RP, Peterson JA, Wilson ME, Brown BS.

Subst Abus. 2010 Jan;31(1):43-52. doi: 10.1080/08897070903442640.

46.

Voltage-gated K+ currents in mouse articular chondrocytes regulate membrane potential.

Clark RB, Hatano N, Kondo C, Belke DD, Brown BS, Kumar S, Votta BJ, Giles WR.

Channels (Austin). 2010 May-Jun;4(3):179-91.

PMID:
20372061
47.

Tetrasubstituted pyridines as potent and selective AKT inhibitors: Reduced CYP450 and hERG inhibition of aminopyridines.

Lin H, Yamashita DS, Xie R, Zeng J, Wang W, Leber J, Safonov IG, Verma S, Li M, Lafrance L, Venslavsky J, Takata D, Luengo JI, Kahana JA, Zhang S, Robell KA, Levy D, Kumar R, Choudhry AE, Schaber M, Lai Z, Brown BS, Donovan BT, Minthorn EA, Brown KK, Heerding DA.

Bioorg Med Chem Lett. 2010 Jan 15;20(2):684-8. doi: 10.1016/j.bmcl.2009.11.061. Epub 2009 Dec 16.

PMID:
20006500
48.

Premature discharge from methadone treatment: patient perspectives.

Reisinger HS, Schwartz RP, Mitchell SG, Peterson JA, Kelly SM, O'Grady KE, Marrari EA, Brown BS, Agar MH.

J Psychoactive Drugs. 2009 Sep;41(3):285-96.

49.

Outcomes of patients with severe combined immunodeficiency treated with hematopoietic stem cell transplantation with and without preconditioning.

Patel NC, Chinen J, Rosenblatt HM, Hanson IC, Krance RA, Paul ME, Abramson SL, Noroski LM, Davis CM, Seeborg FO, Foster SB, Leung KS, Brown BS, Ritz J, Shearer WT.

J Allergy Clin Immunol. 2009 Nov;124(5):1062-9.e1-4. doi: 10.1016/j.jaci.2009.08.041.

50.

Uses of diverted methadone and buprenorphine by opioid-addicted individuals in Baltimore, Maryland.

Gwin Mitchell S, Kelly SM, Brown BS, Schacht Reisinger H, Peterson JA, Ruhf A, Agar MH, O'Grady KE, Schwartz RP.

Am J Addict. 2009 Sep-Oct;18(5):346-55. doi: 10.3109/10550490903077820.

Supplemental Content

Loading ...
Support Center